Nippon Kayaku Co., Ltd. Overview
Nippon Kayaku is a 110-year-old Japanese specialty-chemicals and pharmaceuticals group. Its technology base comes from explosives, dyes, polymers, catalyst design and oncology chemistry. It operates three balanced business domains. Mobility & Imaging (39% of FY2025 sales) makes airbag inflators, seatbelt-pretensioner micro gas generators (MGGs) and squibs, plus optical films and X-ray components. Fine Chemicals (31%) makes semiconductor-grade epoxy and maleimide resins, MEMS resists, inkjet and functional dyes, and acrylic/methacrylic-acid catalysts. Life Science (30%) covers oncology drugs, antibody biosimilars, generics, contract manufacturing and agrochemicals. The company says it holds the top global share in MGGs and acrylic-acid catalysts and a leading share in semiconductor epoxy resins, and it is a leading domestic oncology supplier. In FY2025 it reported record sales of JPY 241.9 bn, with 56% generated overseas. It is now in the first phase of a ten-year plan, Evolution2035, which targets about JPY 500 bn of sales and ROE of 15% or more by FY2035. A cash-rich balance sheet (equity ratio 70%) funds aggressive buybacks.
What the company does
Nippon Kayaku manufactures and sells performance chemicals, automotive pyrotechnic safety components, optical and X-ray components, prescription pharmaceuticals (mainly oncology) and agrochemicals. Per the FY2025 Yuho, it reports three segments ("business domains") made up of eight business units:
Mobility & Imaging (M&I): Safety Systems (airbag inflators, seatbelt-pretensioner MGGs, squibs) and Polatechno (LCD components, LCD-projector components, X-ray analysis equipment components).
Fine Chemicals (FC): Functional Materials (epoxy and maleimide resins, curing agents, reactive flame-retardant resins, acrylic esters, UV-curable resins, MEMS resists, LCD and semiconductor cleaners, LCD sealants, semiconductor equipment). Colorant Materials (inkjet dyes, inkjet textile dyes, industrial inkjet inks, image-sensor materials, dichroic dyes, near-infrared absorbers, textile and paper dyes, resin colorants, thermal developers, pigment derivatives). Catalysts (acrylic acid, acrolein and methacrylic acid catalysts).
Life Science (LS): Pharmaceuticals (antineoplastics, biologics, cardiovascular agents, photodynamic diagnostic agents, in-vitro diagnostics, embolic materials, APIs and intermediates, food additives, health-food ingredients, food-quality preservatives, sanitisers). Agro (insecticides, herbicides, fungicides, acaricides, public-health insecticides, soil fungicides, animal repellents). Real Estate (leasing).
Company's own description (paraphrased from the FY2025 Yuho)
The group's corporate vision is "KAYAKU spirit": to keep supplying society with the best products by combining continual progress with conscience. Under the ten-year plan Evolution2035, launched in April 2026, the stated aspiration is to deliver safety, prosperity and inspiration to people and the planet through Kayaku's technologies. The plan aims to create social and economic value together. Management describes combining proprietary "KAYAKU technologies" with business assets accumulated over decades and a culture of taking on challenges. The named technologies are agrochemical synthesis, anticancer and bio, catalyst design, dye synthesis, polymers and explosives. The named business assets are a global supply network, quality assurance, stable supply and technical-service sales.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue type | Almost entirely product sales: manufactured goods sold B2B, plus prescription drugs sold through Japanese pharmaceutical wholesalers |
| Service revenue | Contract manufacturing (pharma CMO/CDMO, being expanded through the Toyama injectables plant acquired 1 October 2026); minor technical services |
| Licensing | Inbound licensing dominates (taletrectinib, necitumumab, darinaparsin, goserelin). Outbound royalty arrangements are mostly intra-group (e.g., inflator/MGG technology licensed to Kayaku (Huzhou) Safety Equipment; colorant technology to Shanghai Kayaku International Trading) |
| Subscription | — |
| Real estate | Rental income from Port Plaza Nikka (Fukuyama) and Wako Shopping Plaza (Wako, Saitama). Under JPY 2 bn of annual sales (FY2024 guidance basis: JPY 2.0 bn) |
| Revenue recognition | On delivery (domestic) or at the agreed delivery point (exports), net of rebates and returns (Yuho FY2025, accounting policies) |
Value-chain position
Safety Systems: Tier-2 automotive supplier. Inflators, MGGs and squibs go to Tier-1 airbag and seatbelt module makers (e.g., Toyoda Gosei, a disclosed strategic shareholding and 2018 alliance partner) and through them to global and Chinese OEMs. Vertically integrated back into gas-generant (propellant) production.
Polatechno: Component maker for projector makers, HUD module makers, X-ray analyser and electron-microscope OEMs.
Functional Materials: Upstream materials supplier to semiconductor encapsulant makers, substrate and laminate makers, MEMS and image-sensor fabs. Also supplies semiconductor back-end equipment (via Teikoku Taping System).
Colorants: Dye supplier to printer OEMs, ink makers, textile printers and thermal-paper makers.
Catalysts: Supplies proprietary oxidation catalysts to acrylic-acid and methacrylic-acid producers.
Pharmaceuticals: Integrated Japanese marketer and manufacturer of oncology drugs (in-licensed innovative drugs, biosimilars, generics), with API/intermediates export and contract manufacturing.
Agro: Discovery, formulation and sale of crop-protection actives (e.g., flometoquin), domestically and overseas.
Customer types and end-markets
| End-market | Segment | Customer type |
|---|---|---|
| Automotive passive safety | M&I | Tier-1 airbag/seatbelt module makers; Chinese domestic OEM programmes are a key growth driver (Yuho FY2025) |
| Automotive displays (HUD) | M&I | HUD module makers |
| Projectors, analytical instruments | M&I | Projector OEMs; X-ray analyser and electron-microscope OEMs |
| Semiconductors / AI servers / 5G-6G substrates | FC | Encapsulant, laminate and substrate makers; MEMS and image-sensor fabs |
| Printing (consumer, industrial, textile), thermal paper | FC | Printer OEMs, ink formulators, textile printers, thermal-paper makers |
| Acrylic monomers | FC | Acrylic-acid and methacrylic-acid producers |
| Oncology care (Japan) | LS | Hospitals via wholesalers (Suzuken, Toho, Medipal, Alfresa and Vital KSK are disclosed strategic holdings) |
| Agriculture | LS | Distributors and growers (Japan and overseas) |
Independent characterisation
Nippon Kayaku is best understood as a portfolio of niche, mid-cap leadership positions linked by shared chemistry rather than by end-market. Its earnings are cyclically diversified. Automotive volumes, semiconductor inventory cycles and Japanese drug-price revisions rarely trough together. The exception was FY2023, when a semiconductor downturn, steep biosimilar price cuts and a large in-licensing payment coincided and operating margin fell to 3.6%. The structural issues are threefold. First, M&I margins are exposed to pass-through lags on raw materials (gold and explosive components are cited). Second, the pharmaceutical franchise relies on generics and biosimilars, which suffer price revisions under Japan's NHI system. Third, capital efficiency has been weak: ROE stayed below 8% for most of FY2021 to FY2024. Evolution2035 Phase 1 is an explicit attempt to rebuild the portfolio toward higher-value products (new oncology drugs, CDMO, advanced semiconductor resins) and inorganic growth.
Strategy
KAYAKU Vision 2025 (FY2022–FY2025) — review
| KV25 metric (JPY 100 M) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Sales plan | 1,968 | 2,070 | 2,160 | 2,300 |
| Sales actual | 1,983 | 2,017 | 2,225 | 2,418 |
| Operating income plan | 184 | 200 | 225 | 265 |
| Operating income actual | 215 | 73 | 204 | 224 |
Source: Yuho FY2025 ("Results of the Medium-term Business Plan"). FY2025 achievement was 105.2% of plan for sales and 84.7% for operating income. The ROE target of 8% or more was missed (FY2025 actual 9.0% only because of securities gains; management's November 2025 forecast had been 7.7%). The ROIC target is given as 10% in one company document and 6% in another summary; this inconsistency is noted.
Management attributed the shortfalls to the following causes (Nov 2025 policy deck):
M&I: soaring raw-material costs (gold, explosives) and a shrinking monochrome-LCD polariser market.
FC: a delayed semiconductor cycle and slow ramp-up of some new products.
LS: slow market penetration of new drugs and larger-than-expected biosimilar price cuts.
KV25 cash allocation (four-year framework, about JPY 200 bn+). R&D JPY 61.9 bn; M&A and licences JPY 18.9 bn; startup investments JPY 2.6 bn; capex JPY 91.9 bn; dividends JPY 24.6 bn; buybacks JPY 28.0 bn. It was funded partly by debt and cross-shareholding sales (JPY 17.4 bn sold FY2024–FY2025).
Short-term countermeasures adopted in 2024–2025.
-
Exits: projector polariser discontinuation; accelerated discontinuation of non-core drugs; ROIC-based pruning (product groups needing profit improvement are capped at 2% or less of group sales).
-
Capital policy: total payout of 100% or more until ROE reaches 8%; progressive dividend; cancellation of treasury stock above 0.5% of issued shares.
-
Pricing reforms ("profit over sales").
Evolution2035 — long-term plan (FY2026–FY2035)
Aspiration (paraphrased): deliver safety, prosperity and inspiration to people and the planet through Kayaku technologies.
- Ten-year targets (July 2026 investor presentation via Quartr): sales of about JPY 500 bn by FY2035, roughly double FY2025, and ROE of 15% or more. The plan emphasises inorganic growth (new businesses, M&A) and, in pharma, a shift toward new drugs and contract manufacturing. Pharma management has said it wants new drugs to reach about 30% of pharma sales within roughly ten years (Shimada, Jiho, Feb 2026).
Three phases: Phase 1 runs FY2026–FY2028; Phases 2 and 3 run to FY2035.
Named growth themes (Nov 2025 policy deck): functional dyes, new pharmaceuticals, drone safety devices, flying-car safety devices, space industry, new semiconductor materials, carbon-neutral catalysts, anion-exchange membranes for hydrogen production (NEDO-adopted project), digital-printing inks and X-ray business.
Evolution2035 Phase 1 (FY2026–FY2028) — medium-term targets (Yuho FY2025)
| Target | FY2028 |
|---|---|
| Net sales | JPY 300 bn |
| Operating income | JPY 36 bn (12% margin) |
| ROE | 10% or more (achieve 8% early, then double digits) |
| After-tax ROIC | 7% or more |
Five company-wide priorities:
-
Build a resilient business portfolio.
-
Turn KV25 investments into results (raise utilisation of the new epoxy and industrial inkjet capacity; automation).
-
Optimise cash allocation.
-
Evolve the organisation for efficiency and speed.
-
Invest strategically in human capital.
New "Mirai Biz Center" for businesses beyond the existing framework; active use of open innovation, in-licensing, alliances and M&A.
Pharma structural shift (Jiho, 13 May 2026): grow share of new drugs introduced through FY2025, launch biosimilars and generics on a schedule, and expand contract manufacturing.
Treat these as not publicly verified here.
Strategic initiatives announced in the last 24 months
| Date | Initiative | Type |
|---|---|---|
| Nov 2024 – Mar 2026 | Buybacks of JPY 7 bn then JPY 17 bn; cancellations of 5.5 M, 5.0 M and 11.3 M shares | Capital policy |
| 28 Mar 2025 | "Management conscious of cost of capital and share price" disclosure | Governance / capital |
| FY2024–FY2025 | JPY 17.4 bn of strategic shareholdings sold (9 listed names fully exited in FY2025, incl. MUFG, Shin-Etsu, Meiji HD, Toyota Tsusho) | Balance-sheet efficiency |
| 2,025 | Gas cogeneration at Takasaki; multi-site energy service; solar additions | Decarbonisation |
| Sep–Nov 2025 | Ibtrogy approval and launch | New drug |
| 2025–2026 | Takasaki integrated QA building (JPY 4.2 bn), injectables line and biologics line | Pharma capacity |
| 30 Mar 2026 | Acquisition of the Toyama injectables CDMO plant | Pharma CDMO |
| Apr 2026 | Evolution2035 launch; Mirai Biz Center | Strategy |
| 12 May 2026 | Phase 1 targets; JPY 15 bn buyback (to Mar 2027) | Strategy / capital |
| 21 May 2026 | Zoladex marketing authorisation transfer from AstraZeneca | Product acquisition |
| Sep 2026 | Sanko Chemical Industry 100% (squeeze-out) | Group simplification |
| Ongoing | Squib, MGG and inflator capacity in CN, MX, MY and CZ; epoxy (Asa) and dry-film resist (Fukuyama) plants | Capacity |
| Ongoing | NEDO-adopted anion-exchange membrane for water electrolysis; PARASAFE with Rainmaker | Technology bets |
Management guidance (FY2026, year ending March 2027)
| Item | Initial (12 May 2026) | Revised (3 Aug 2026) |
|---|---|---|
| Net sales (JPY bn) | 260.6 | 270.9 (+12.0% YoY) |
| Operating income (JPY bn) | 25.4 | 27.3 (+21.6%) |
| Ordinary income (JPY bn) | 25.2 | 27.0 |
| Net income attributable (JPY bn) | 22.3 | 22.9 |
| EPS (JPY) | — | 158.66 |
| DPS (JPY) | 66 (33/33) | 66 (unchanged) |
| ROE / ROIC | 8.2% / 5.6% | 8.4% / 6.0% |
Sources: Yahoo! Finance Japan, Monex and Quartr. First-half sales guidance was raised by JPY 10.3 bn to JPY 133.8 bn.
Products & Services
Pricing models are not publicly disclosed for industrial products; they are B2B contract pricing with raw-material pass-through mechanisms that management is renegotiating. Pharmaceutical prices are set by Japan's NHI price list. Launch years are given only where a source confirms them.
Mobility & Imaging — Safety Systems
| Product | Description / capabilities | Target customer | Status / notes |
|---|---|---|---|
| Airbag inflators (cylinder type) | Pyrotechnic gas generators that inflate side and curtain airbags. A next-generation cylinder inflator design was completed and entered production and sale in FY2025 | Airbag module makers / OEMs | Manufactured in Himeji (JP), Huzhou (CN) and Sendayan (MY). The FY2025 Yuho lists two Huzhou inflator lines (JPY 697 M and JPY 960 M) |
| Airbag inflators (disc type) | Driver and passenger frontal inflators; next-generation disc inflator in development | Module makers / OEMs | Development stage (Yuho FY2025) |
| Micro gas generators (MGGs) | Actuators for seatbelt pretensioners. Company claims the top global share (July 2026 investor presentation via Quartr) | Seatbelt makers / OEMs | Made in Czech Republic, China, Mexico and Malaysia; Mexico and Malaysia MGG line expansions completing 2026 |
| Squibs (initiators) | Electrically fired initiators used in inflators, MGGs and other pyrotechnic devices. Company claims a leading global share | Safety-system makers | Squib capacity being added in Czechia (JPY 848 M), Huzhou (JPY 2,185 M, completing Sept 2027), Mexico (JPY 745 M) and Malaysia (JPY 1,104 M) |
| Gas generants | Propellant formulations | Internal / affiliates | Made at Jablůnka (CZ) |
| PARASAFE® drone parachute | Parachute recovery system for drones; adopted by US company Rainmaker for FAA-approved high-altitude cloud-seeding operations | Drone operators | Commercial (Aero Business Promotion Dept.) |
| Steerable parachute recovery system | Collision-avoiding parachute system for "flying cars" (eVTOL) | eVTOL developers (NK invested in SkyDrive in 2022) | Development |
| Fire-suppression components | Pyrotechnic-actuated initial fire suppression, e.g., for collection of waste batteries | Battery recyclers / industrial | Research stage (Technology Division) |
| Non-automotive pyrotechnic devices | Pyrotechnics for applications beyond auto safety | Various | Development begun (Yuho FY2025) |
Mobility & Imaging — Polatechno
| Product | Description | Target customer | Status / notes |
|---|---|---|---|
| Dye-based polarising films (automotive high-durability) | Integrated from dichroic dye design and synthesis through film forming | In-vehicle display makers | Polariser sales flat in FY2025 |
| Light-shielding plates for head-up displays (HUD) | Optical parts that block sunlight-induced heat and glare in HUDs | HUD module makers | Growing; adoption rising in EVs (Yuho FY2025) |
| LCD-projector components | Inorganic and wire-grid polarisers and optical components (Moxtek, Wuxi Polatechno Optical) | Projector OEMs | Declining. Projector polarisers are being discontinued as a profit-improvement action (Nov 2025 Evolution2035 policy deck) |
| X-ray analysis equipment components | X-ray tubes, windows and detectors (Moxtek; Rayspec silicon drift detectors and signal processors) | Portable XRF and electron-microscope OEMs | Fell in FY2025 on customer inventory adjustment; distinctive products in development |
| Special retardation films | Dejima Optical Films (Netherlands) | Display makers | Niche |
| Monochrome-LCD polarisers | Legacy product | Industrial LCD makers | Market shrinking (company cites as a KV25 profit drag) |
Fine Chemicals — Functional Materials
| Product | Description / application | Target customer | Notes |
|---|---|---|---|
| Epoxy resins (semiconductor grade) | Insulating resins for encapsulants and substrates. Monex profile states world No. 1 for semiconductor encapsulant epoxy | Encapsulant and laminate makers | New Asa epoxy plant (JPY 7.45 bn; JPY 7.31 bn spent), completion pushed from Jan 2026 to Jan 2028 |
| Maleimide resins | High-heat, low-dielectric resins for AI/5G-6G substrates | Substrate makers | Growth product |
| Curing agents for epoxy | Hardeners | Formulators | — |
| Reactive flame-retardant resins | Halogen-free flame retardancy | Laminate makers | — |
| Acrylic esters / UV-curable resins (KAYARAD® series) | Resins for resists and coatings; produced in Wuxi | Resist and coating makers | — |
| MEMS resists (liquid and dry film), incl. the SU-8 family via Kayaku Advanced Materials | Thick-film photoresists for MEMS and image sensors | MEMS and CMOS sensor fabs | Dry-film resist plant at Fukuyama (JPY 850 M), completion deferred to Apr 2028 |
| LCD and semiconductor cleaners | Process chemicals | Fabs | — |
| LCD sealants | Display assembly | Panel makers | — |
| Semiconductor manufacturing equipment | Laminators, removers, mounters, UV irradiators (Teikoku Taping System) | Back-end semiconductor assemblers | Entered via 2021 investment |
| Epoxy for carbon-fibre-reinforced plastics | Composite matrix resins | Composite makers | Development focus |
| Next-generation materials in R&D | Low-dielectric, low-warpage resins; high-heat materials for power semiconductors; new liquid materials | — | Yuho FY2025 R&D section |
Fine Chemicals — Colorant Materials
| Product | Description | Target customer | Notes |
|---|---|---|---|
| Inkjet printer dyes (consumer) | Dyes for home and office inkjet | Printer OEMs | Declined in FY2025 |
| Inkjet textile-printing dyes | Digital textile printing | Textile printers | — |
| Industrial inkjet inks | High-speed, high-quality inks for diverse media | Industrial printers | Capacity added under KV25; utilisation improvement targeted |
| Image-sensor materials | Colour materials for CMOS sensors | Sensor makers | — |
| Dichroic dyes for light-control (smart) glass | Dyes enabling dimmable glazing | Smart-glass makers | New product; sales began in FY2025 |
| Near-infrared absorbers | Functional dyes | Optics and security printing | — |
| Textile and paper dyes | Conventional dyes (Wuxi Advanced Kayaku, Thailand) | Dyehouses | Mature |
| Resin colorants | Polymer colouring | Plastics processors | — |
| Thermal developers (colour developers) | Non-phenol developers for thermal paper | Thermal-paper makers | Grew in FY2025 as US regulation drove non-phenol substitution |
| Pigment derivatives (synergists) | Dispersion aids | Pigment and ink makers | — |
Fine Chemicals — Catalysts
| Product | Description | Target customer | Notes |
|---|---|---|---|
| Acrylic-acid production catalysts | Two-stage propylene oxidation catalysts. Company claims the top global share | Acrylic-acid producers | Shipments weighted to the second half; FY2025 sales up on a strong Q4 |
| Acrolein production catalysts | First-stage oxidation | Same | — |
| Methacrylic-acid production catalysts | High-yield, long-life catalysts | MMA/MAA producers | — |
| Green / carbon-neutral catalysts | Decarbonisation and hydrogen-economy catalysts; bio-based materials work started | Chemical producers | R&D |
Life Science — Pharmaceuticals
| Product | Type / indication | Origin / partner | Status |
|---|---|---|---|
| Ibtrogy® Capsules 200 mg (taletrectinib adipate) | ROS1 TKI for unresectable advanced or recurrent ROS1-fusion NSCLC; active against resistance mutations such as G2032R | In-licensed from AnHeart (now Nuvation Bio) in Oct 2023: USD 40 M upfront plus milestones and royalties | Approved 19 Sep 2025; launched 12 Nov 2025 (fourth ROS1 agent in Japan). Eisai holds ex-Japan/US/China rights from Jan 2026 |
| Portrazza® (necitumumab) | Anti-EGFR antibody for squamous NSCLC | Licensed from Eli Lilly (Mar 2019) | Marketed; label-expansion trial ongoing (Yuho FY2025) |
| Darvias® (darinaparsin) | Relapsed/refractory peripheral T-cell lymphoma | Licensed from Solasia Pharma (Oct 2021); NK holds 12 M Solasia shares | Marketed |
| Alaglio® (aminolevulinic acid) | Photodynamic diagnostic agent | Partnership (licensor not confirmed in sources) | Marketed; named among new drugs to penetrate |
| Zoladex® 3.6 mg Depot / LA 10.8 mg Depot (goserelin) | LH-RH agonist for prostate cancer, premenopausal breast cancer, endometriosis | Marketing authorisation being taken over from AstraZeneca K.K. (contract 21 May 2026; lump-sum payment at completion) | Transition timing not confirmed in sources |
| Antibody biosimilars: Adalimumab BS, Bevacizumab BS (plus legacy infliximab and trastuzumab biosimilars) | Biosimilars | In-house / partners | Adalimumab and bevacizumab BS gaining share (FY2025) |
| Oncology generics: Lenalidomide capsules, Abiraterone acetate tablets | Generics | In-house | Launched in FY2025 |
| Legacy oncology portfolio (about 20 anticancer agents per the Monex profile; incl. bleomycin heritage) | Branded and generic cytotoxics | In-house | Some non-core products being discontinued |
| Paclitaxel polymeric micelle (NanoCarrier licence, 2002) | Nanoparticle oncology formulation | NanoCarrier | Licence in force (Yuho material contracts) |
| LHRH antagonist (Aeterna Zentaris licence, 2006) | Hormonal oncology | Aeterna Zentaris | Licence in force |
| Bladder-cancer agent (Spectrum licence, 2009; Japan and Asia ex-Korea) | Urology oncology | Spectrum | Licence in force |
| In-vitro diagnostics, embolic materials, cardiovascular agents | Hospital products | Various | Diagnostics declined in FY2025 |
| APIs and intermediates; exports; contract manufacturing | B2B pharma | In-house; Toyama plant from Oct 2026 | Domestic API, exports and contract manufacturing declined in FY2025; CDMO is a Phase 1 growth pillar |
| Food additives, health-food ingredients, food-quality preservatives, sanitisers | Food-tech (Nippon Kayaku Food Techno) | In-house | — |
| Buparlisib (pan-PI3K, Japan rights via the Adlai Nortye relationship) | Head & neck cancer candidate | Adlai Nortye | Discontinued. Adlai Nortye reported the Phase 3 BURAN trial missed its primary overall-survival endpoint and ended development (30 May 2025) |
Life Science — Agro and Real Estate
| Product | Description | Notes |
|---|---|---|
| Flometoquin formulations | Insecticide; main overseas growth product | FY2025 overseas sales grew; volume expansion is a priority |
| NK-518 | New in-house insecticide | Building the data package for registration |
| Formulation-improved products and functional spreaders | Formulation technology | One new registration in FY2025 |
| Biostimulants, low-environmental-impact materials | New agri inputs | Research and in-licensing |
| Herbicides, fungicides, acaricides, soil fungicides, public-health insecticides, animal repellents | Core domestic portfolio | Made at the Kashima Plant |
| Real estate: Port Plaza Nikka (Fukuyama); Wako Shopping Plaza (Saitama) | Leasing | Flat in FY2025 |
Financial Narrative
All figures are consolidated, JPY M, Japanese GAAP. Sources: Yuho FY2021–FY2025; S&P Global Market Intelligence data via StockAnalysis for some cash-flow and balance-sheet line items. Ratios are computed by the analyst from those figures unless otherwise labelled.
Income statement
EBITDA is operating income plus depreciation and amortisation (Envalith; consistent with D&A in the cash-flow statement). The payout series is from Finboard and the FY2025 Yuho.
Margins
Revenue CAGR: FY2021 to FY2025 (4 years) = 6.96%. FY2020 (JPY 173,381 M) to FY2025 (5 years) = 6.9%.
Balance sheet
FY2025 debt composition: short-term borrowings JPY 800 M plus current portion of long-term loans JPY 10,212 M; long-term loans JPY 24,171 M; straight bonds JPY 14,000 M (Yuho FY2025).
Ratios
Management's own KV25 ROIC (company definition) was 8.3% (FY2022), 2.7% (FY2023), 7.1% (FY2024) and about 7.3% forecast for FY2025 (Nov 2025 policy deck via EDINET DB). These differ from the analyst figures above because the definitions differ. StockAnalysis reports TTM ROIC of 6.04%.
Commentary — trends, inflections and drivers
Growth. Sales have grown in each of the last five years, hitting a fifth consecutive record of JPY 241.9 bn in FY2025. Growth came mostly from M&I volume (Chinese domestic OEM programmes, steady global auto production) and yen weakness. Overseas sales were 56% of the total. FY2023 was the only near-stall (+1.7%), when FC sales fell 10.9% in the semiconductor down-cycle.
Profitability inflection. Gross margin has eroded structurally, from 34.6% in FY2021 to 30.1% in FY2025, a fall of 4.5 points. Three causes stand out: raw-material and energy inflation (including gold and explosive inputs in safety products) that pass-through has only partly offset; a mix shift toward lower-margin Safety Systems; and NHI price cuts on biosimilars. The FY2023 collapse in operating margin (3.6%) was amplified by an R&D spike. R&D within SG&A jumped to JPY 19.4 bn from JPY 12.9 bn, which is consistent with expensing the USD 40 M taletrectinib upfront payment (the attribution is the analyst's inference from timing). Since then operating margin has recovered to about 9.3%, but it remains below the 11% of FY2021–FY2022. Management cites price renegotiation and a "profit over sales" mindset as the main FY2026 levers.
Below-the-line support. FY2025 net income (+40.7%) was flattered by JPY 9.4 bn of gains on sales of cross-shareholdings. Against that, the effective tax rate rose to 26.4% from 20.1%. Excluding the securities gains, recurring profit growth was about 14% (ordinary income +14.4%). FY2024 had included a JPY 2.6 bn impairment of investment securities. This coincides with the failure of buparlisib at Adlai Nortye, an NK shareholding; the link is inferred, not confirmed in sources.
Cash flow and capex cycle. Operating cash flow rose steadily to JPY 28.8 bn, but free cash flow compressed sharply. Capex tripled from JPY 8.7 bn (FY2021) to JPY 29.3 bn (FY2024) and JPY 24.5 bn (FY2025) to fund the Asa epoxy plant, squib, MGG and inflator lines in China, Mexico, Malaysia and Czechia, and Takasaki's injectables, biologics and integrated QA buildings. Inventories climbed to 182 days, and working capital absorbed JPY 7.7 bn in FY2025. As a result, record shareholder returns (JPY 27.1 bn in FY2025) were funded by asset sales (JPY 13.3 bn of securities) and new borrowing (net +JPY 7.1 bn).
Balance sheet. The group has moved from a JPY 37 bn net-cash position (FY2021) to near net-neutral (JPY 5.3 bn net cash). It is deliberately lifting leverage to cut its equity-heavy capital structure, with the equity ratio falling from 78.7% to 70.0%. Debt/EBITDA is still only about 1.3x, so there is ample capacity for the M&A-led growth Phase 1 envisages. Goodwill is negligible (JPY 0.5 bn).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Business units | Principal subsidiaries/affiliates |
|---|---|---|
Mobility & Imaging | Safety Systems; Polatechno | Kayaku Safety Systems Europe a.s. (CZ); Kayaku (Huzhou) Safety Equipment (CN); Kayaku Safety Systems de Mexico; Kayaku Safety Systems Malaysia; Nippon Kayaku America (Troy, MI); Nippon Kayaku Korea; Moxtek (US); Wuxi Polatechno Optical (CN); Dejima Tech / Dejima Optical Films (NL); Polatechno Co. (JP, now a land-holding entity); Rayspec (UK) |
Fine Chemicals | Functional Materials; Colorant Materials; Catalysts | Kowa Sangyo; Nikka Fine Techno; Kayaku Chemical (Wuxi); Kayaku Advanced Materials (US); Teikoku Taping System; Wuxi Advanced Kayaku Chemical (80%); Shanghai Kayaku International Trading; Nippon Kayaku (Thailand); Euro Nippon Kayaku (Germany) |
Life Science | Pharmaceuticals; Agro; Real Estate | Nippon Kayaku Food Techno; Taiwan Nikka; Wako Toshi Kaihatsu; Cultivecs (37.3%, equity method) |
Other (outside segments) | Industrial explosives, organic peroxides, chemicals and safety products | Kayaku Japan (50%), Kayaku Nouryon (25%), Sanko Chemical Industry (45% at FY2025-end; 100% from Oct 2026) |
Revenue by Segment
| Segment (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Mobility & Imaging sales | 71,869 | 81,201 | 91,376 | 94,714 |
Fine Chemicals sales | 64,047 | 57,072 | 66,206 | 74,142 |
Life Science sales | 62,463 | 63,518 | 65,001 | 72,994 |
Consolidated net sales | 198,380 | 201,791 | 222,584 | 241,851 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment profit (JPY Mn)
| Segment profit (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Mobility & Imaging profit | 8,215 | 8,028 | 13,311 | 10,654 |
Fine Chemicals profit | 10,221 | 5,183 | 9,899 | 11,929 |
Life Science profit | 10,668 | 2,410 | 6,354 | 9,680 |
Total segment profit | 29,104 | 15,621 | 29,564 | 32,263 |
Unallocated / corporate (incl. corporate R&D) | -7,599 | -8,284 | -9,163 | -9,809 |
Consolidated operating income | 21,505 | 7,337 | 20,401 | 22,454 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
M&I segment margin | 11.4 | 9.9 | 14.6 | 11.2 |
FC segment margin | 16.0 | 9.1 | 15.0 | 16.1 |
LS segment margin | 17.1 | 3.8 | 9.8 | 13.3 |
M&I sales growth YoY | — | 13.0 | 12.5 | 3.7 |
FC sales growth YoY | — | -10.9 | 16.0 | 12.0 |
LS sales growth YoY | — | 1.7 | 2.3 | 12.3 |
M&I share of sales | 36.2 | 40.2 | 41.1 | 39.2 |
FC share of sales | 32.3 | 28.3 | 29.7 | 30.7 |
LS share of sales | 31.5 | 31.5 | 29.2 | 30.2 |
Segment Assets & Liabilities
| Metric (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
M&I segment assets | 110,514 | 124,179 | 130,799 | 144,188 |
FC segment assets | 78,169 | 82,555 | 94,497 | 97,021 |
LS segment assets | 83,674 | 84,765 | 86,720 | 104,101 |
M&I capex | 4,609 | 6,752 | 9,400 | 6,700 |
FC capex | 4,843 | 7,776 | 9,000 | 4,000 |
LS capex | 2,636 | 3,864 | 6,600 | 4,000 |
M&I depreciation | 7,004 | 7,013 | 6,734 | 7,107 |
FC depreciation | 3,593 | 3,607 | 3,811 | 4,978 |
LS depreciation | 2,616 | 2,754 | 2,795 | 2,943 |
Legacy Segment Details
| Legacy segment | Sales (JPY Mn) | Segment profit (JPY Mn) | Margin (%) |
|---|---|---|---|
Functional Chemicals | 77,152 | 11,501 | 14.9 |
Pharmaceuticals | 52,083 | 8,645 | 16.6 |
Safety Systems | 46,112 | 6,306 | 13.7 |
Others (agro, real estate; derived residual) | 9,458 | — | — |
Business Units
| Business unit | FY2024 forecast (JPY 100 M) |
|---|---|
Safety Systems | 715 |
Polatechno | 205 |
Functional Materials | 336 |
Colorant Materials | 258 |
Catalysts | 79 |
Pharmaceuticals | 531 |
Agro | 92 |
Real Estate | 20 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 184,805 | 198,380 | 201,791 | 222,584 | 241,851 |
Sales growth YoY (%) | 6.6 | 7.3 | 1.7 | 10.3 | 8.7 |
Gross profit (JPY Mn) | 63,967 | 66,752 | 61,301 | 71,482 | 72,880 |
SG&A incl. R&D (JPY Mn) | 42,916 | 45,247 | 53,964 | 51,080 | 50,426 |
Operating income (JPY Mn) | 21,050 | 21,505 | 7,337 | 20,401 | 22,454 |
EBITDA (JPY Mn) | 35,149 | 35,745 | 21,739 | 34,478 | 38,213 |
Ordinary income (JPY Mn) | 23,154 | 23,025 | 12,562 | 22,266 | 25,478 |
Pre-tax income (JPY Mn) | 23,700 | 20,972 | 7,205 | 22,007 | 33,592 |
Income taxes (JPY Mn) | 6,455 | 5,929 | 3,026 | 4,428 | 8,880 |
Net income attributable to owners (JPY Mn) | 17,181 | 14,984 | 4,113 | 17,508 | 24,641 |
EPS basic (JPY) | 101.70 | 89.36 | 24.80 | 107.17 | 161.18 |
EPS diluted (JPY) | 101.65 | 89.33 | 24.79 | 107.16 | 161.18 |
Dividend per share (JPY) | 40 | 45 | 45 | 60 | 66 |
Payout ratio (%) | 39.4 | 50.4 | 181.5 | 56.0 | 40.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 34.6 | 33.6 | 30.4 | 32.1 | 30.1 |
Operating margin | 11.4 | 10.8 | 3.6 | 9.2 | 9.3 |
EBITDA margin | 19.0 | 18.0 | 10.8 | 15.5 | 15.8 |
Net margin | 9.3 | 7.6 | 2.0 | 7.9 | 10.2 |
Liquidity & Coverage Ratios and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 315,459 | 322,858 | 363,173 | 373,708 | 398,736 |
Cash & equivalents, CF basis (JPY Mn) | 52,962 | 53,096 | 64,777 | 57,926 | 53,368 |
Cash + short-term investments (JPY Mn) | 53,645 | 54,347 | 66,177 | 59,762 | 54,495 |
Short-term debt incl. current LTD (JPY Mn) | 7,176 | 3,380 | 13,450 | 7,212 | 11,013 |
Long-term debt incl. bonds (JPY Mn) | 9,474 | 16,200 | 18,000 | 34,884 | 38,171 |
Total debt (JPY Mn) | 16,650 | 19,580 | 31,450 | 42,096 | 49,184 |
Net debt, negative = net cash (JPY Mn) | -36,995 | -34,767 | -34,727 | -17,666 | -5,311 |
Net assets (JPY Mn) | 246,425 | 255,027 | 270,548 | 268,520 | 280,104 |
Goodwill + intangibles (JPY Mn) | 7,586 | 6,539 | 3,696 | 4,051 | 3,755 |
Inventories (JPY Mn) | 55,834 | 71,106 | 67,008 | 71,541 | 84,309 |
Working capital (JPY Mn) | 130,083 | 146,988 | 143,331 | 151,188 | 155,025 |
Equity ratio (%) | 77.8 | 78.7 | 74.2 | 71.6 | 70.0 |
Book value per share (JPY) | 1,459.06 | 1,532.35 | 1,625.18 | 1,673.24 | 1,878.87 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 23,141 | 20,039 | 23,242 | 25,530 | 28,784 |
Capex, PP&E purchases (JPY Mn) | 8,696 | 12,221 | 15,036 | 29,259 | 24,498 |
Free cash flow (JPY Mn) | 14,445 | 7,818 | 8,206 | -3,729 | 4,286 |
Depreciation & amortisation (JPY Mn) | 14,099 | 14,240 | 14,402 | 14,077 | 15,759 |
Dividends paid (JPY Mn) | 5,070 | 7,550 | 7,855 | 7,395 | 10,559 |
Share buybacks (JPY Mn) | 3,000 | 3,000 | 2 | 7,882 | 16,581 |
Total cash returned (JPY Mn) | 8,070 | 10,550 | 7,857 | 15,277 | 27,140 |
Investing cash flow (JPY Mn) | -10,641 | -15,158 | -19,409 | -27,313 | -17,184 |
Financing cash flow (JPY Mn) | -11,090 | -7,950 | 3,823 | -4,756 | -20,235 |
Proceeds from sale of investment securities (JPY Mn) | — | — | — | 6,016 | 13,297 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%, Yuho) | 7.3 | 6.0 | 1.6 | 6.5 | 9.0 |
ROA (%, NI / average total assets) | 5.6 | 4.7 | 1.2 | 4.8 | 6.4 |
ROIC (%, NOPAT / (equity + debt − cash)) | 7.3 | 7.0 | 1.8 | 6.5 | 6.0 |
Current ratio (x) | 3.84 | 4.76 | 3.40 | 3.72 | 3.38 |
Debt / equity (x) | 0.07 | 0.08 | 0.12 | 0.16 | 0.18 |
Net debt / EBITDA (x, negative = net cash) | -1.05 | -0.97 | -1.60 | -0.51 | -0.14 |
Interest coverage (x, OI / interest expense) | 257 | 209 | 58 | 91 | 48 |
Asset turnover (x) | 0.61 | 0.62 | 0.59 | 0.60 | 0.63 |
DSO (days, trade receivables) | 123.5 | 102.1 | 112.2 | 105.6 | 106.7 |
DIO (days) | 168.7 | 197.2 | 174.1 | 172.8 | 182.1 |
DPO (days) | 54.4 | 45.0 | 49.4 | 48.0 | 52.3 |
Cash conversion cycle (days) | 237.8 | 254.3 | 236.9 | 230.4 | 236.5 |
Revenue by Region and Revenue by Region (%)
| Region (JPY Mn) | FY2024 | FY2025 |
|---|---|---|
Japan | 96,447 | 106,360 |
China | 46,434 | 51,633 |
Other Asia | 25,766 | 29,503 |
United States | 28,691 | 24,219 |
Other regions (incl. Europe, Americas ex-US) | 25,244 | 30,136 |
Total | 222,582 | 241,851 |
Overseas sales ratio (%) | 56.7 | 56.0 |
Region growth / mix (%)
| Region growth / mix (%) | FY2025 YoY growth | FY2025 share of sales |
|---|---|---|
Japan | 10.3 | 44.0 |
China | 11.2 | 21.3 |
Other Asia | 14.5 | 12.2 |
United States | -15.6 | 10.0 |
Other | 19.4 | 12.5 |
Point in Time Details
| Point in time | Price (JPY) | Source |
|---|---|---|
25 Sep 2026 (latest retrieved close) | 2,129.5 | Kabuyoho |
4 Aug 2026 | 1,944.5 | Monex |
28 Jul 2026 | 1,944.5 | StockAnalysis |
FY2025 high / low (Apr 2025 – Mar 2026) | 2019 / 1219 | Yuho FY2025 |
FY-end share price, implied (JPY) | FY2021 | FY2022 |
Implied from Yuho P/E × EPS | 1,159 | 1,188 |
FY high | 1,322 | 1,289 |
FY low | 982 | 1,037 |
Performance | Value | — |
52-week price change (to 28 Jul 2026) | +43.7% (S&P via StockAnalysis) | — |
≈1-year (implied Mar-2025 FY-end ~1,415 → 2,129.5 on 25 Sep 2026) | ≈ +50% (approximate; derived) | — |
5-year total shareholder return (Mar 2021 = 100 → Mar 2026) | 188.2 vs. TOPIX incl. dividends 202.2 (Yuho FY2025): underperformed TOPIX by about 14 points | — |
3-year TSR (Mar 2023 → Mar 2026, from Yuho index) | 188.2 / 119.9 = +57% vs. TOPIX 202.2 / 107.9 = +87% (derived) | — |
Beta (5-year) | 0.49 | — |
Valuation Multiples
| Multiple | Nippon Kayaku | Source / date | Peer reference |
|---|---|---|---|
P/E (forecast) | 13.8x | Kabuyoho, 25 Sep 2026 | Daicel ≈11.8x (Finboard) |
P/E (trailing, FY2025 EPS 161.18) | ≈13.2x at JPY 2,129.5 | Derived | — |
P/B | 1.11x | Kabuyoho, 25 Sep 2026 | — |
EV/EBITDA | 7.0x (28 Jul 2026, StockAnalysis); 8.3x (Envalith, Jul 2026) | Sources differ on EV | — |
EV/Sales | 1.11x | StockAnalysis, 28 Jul 2026 | — |
Dividend yield (forecast) | 3.10% | Kabuyoho, 25 Sep 2026 | — |
DOE | 3.6% | EDINET DB | — |
Capital Markets
| Item | Value |
|---|---|
Consensus target price | JPY 2,800 (Kabuyoho, 25 Sep 2026); was JPY 2,550 on 29 Jul 2026 |
Implied upside | ≈31% vs. JPY 2,129.5 |
Consensus FY2026 ordinary income | JPY 29.5 bn (+15.8%) vs. company JPY 27.0 bn (Sep 2026); was JPY 26.85 bn in Jul 2026 |
Dividend (JPY per share)
| Dividend (JPY per share) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim | 15.0 | 20.0 | 22.5 | 22.5 | 30.0 |
Year-end | 25.0 | 25.0 | 22.5 | 37.5 | 36.0 |
Annual | 40.0 | 45.0 | 45.0 | 60.0 | 66.0 |
Authorised Details
| Authorised | Period | Limit | Executed | Cancellation |
|---|---|---|---|---|
13 May 2024 | 2024 | — | 2,374,800 shares | — |
11 Nov 2024 | 18 Nov 2024 – 30 May 2025 | 6.5 M shares / JPY 7.0 bn | 4,015,800 shares / ≈JPY 5.25 bn (ended 10 Apr 2025) | 5.5 M shares (25 Nov 2024); 5,003,570 shares (23 May 2025) |
28 Mar 2025 | 14 Apr 2025 – 31 Mar 2026 | 14.0 M shares / JPY 17.0 bn | 11,224,800 shares / JPY 16.2 bn (ended 26 Mar 2026) | 11.3 M shares (22 May 2026) |
12 May 2026 | 13 May 2026 – 31 Mar 2027 | 13.0 M shares / JPY 15.0 bn | — | Policy: cancel holdings above 0.5% of issued shares |
Credit Ratings
| Agency | Rating / outlook |
|---|---|
Moody's | Not rated / not located |
S&P | Not rated / not located |
Fitch | Not rated / not located |
R&I / JCR (domestic) | Not located in this research |
Capital Instruments
| Instrument (JPY Mn) | ≤1 yr | 1–2 yrs | 2–3 yrs | 3–4 yrs | 4–5 yrs | >5 yrs |
|---|---|---|---|---|---|---|
Long-term loans | 10,212 | 10,212 | 7,412 | 5,012 | 1,512 | 21 |
Short-term loans | 800 | 0 | 0 | 0 | 0 | 0 |
Lease obligations | 106 | 102 | 71 | 56 | 44 | 306 |
Analyst Conclusions
Guidance and consensus
FY2026 guidance (revised 3 August 2026) calls for sales of JPY 270.9 bn (+12.0%), operating income of JPY 27.3 bn (+21.6%, margin about 10.1%), ordinary income of JPY 27.0 bn and net income of JPY 22.9 bn. Net income is lower than FY2025 because smaller securities gains are expected. The dividend is JPY 66, ROE 8.4% and ROIC 6.0%. The September 2026 sell-side consensus (ordinary income JPY 29.5 bn) sits about 9% above company guidance, which implies the market expects a further upward revision at the 1H results in November 2026. The Phase 1 trajectory requires operating income to compound about 17% a year from JPY 22.5 bn (FY2025) to JPY 36 bn (FY2028), with margin expanding from 9.3% to 12%.
Bull case
-
Earnings inflection is under way. Q1 FY2026 delivered record sales (+23.1%) and ordinary income +81.7%, prompting a JPY 10.3 bn sales upgrade in the first quarter of the plan. Pharma Q1 sales were up about 28% (Jiho), suggesting Ibtrogy, new generics and biosimilars are scaling.
-
Capital discipline is real. The company has cancelled about 21.8 M shares (≈13% of the March 2024 issued count) since November 2024. Total payout was 106% in FY2025. A further JPY 15 bn buyback runs to March 2027 (about 5% of market cap). Cross-shareholdings are being liquidated, a classic Japanese governance rerating catalyst at P/B of about 1.1x.
-
Structural growth exposure at a value multiple. AI-server resins (FC margin 16.1%), Chinese safety content and Japanese oncology CDMO are bought at about 13.8x forward P/E and about 7–8x EV/EBITDA. A balance sheet with debt/EBITDA of about 1.3x leaves room for accretive M&A toward the JPY 500 bn ambition.
Bear case
-
Margins have not structurally recovered. Gross margin fell 4.5 points in four years, and M&I profit dropped 20% in FY2025 on raw materials. The KV25 operating-income target was missed by 15%, and FY2028's JPY 36 bn target implies execution well beyond the past record (JPY 21.5 bn).
-
Cash generation is thin. Free cash flow was −JPY 3.7 bn and JPY 4.3 bn in the last two years. FY2025 net income relied on JPY 9.4 bn of securities gains. Shareholder returns have been financed by asset sales and debt (net cash fell from JPY 37 bn to JPY 5 bn). That pace cannot continue indefinitely without stronger FCF.
-
Pharma and geopolitical tail risks. Annual NHI cuts and a difficult biosimilar market, pipeline concentration on in-licensed assets (buparlisib already failed) and 21% China sales exposure amid US tariffs could derail the plan. The five-year TSR (188) still lags TOPIX (202).
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Early-to-mid Nov 2026 | 1H FY2026 results: guidance versus consensus (JPY 29.5 bn ordinary); M&I raw-material pass-through; interim DPS JPY 33 |
| 13 Oct 2026 onward | Sanko Chemical 100% ownership; Toyama plant integration and capex plans |
| Late 2026 | Takasaki integrated QA building (Oct 2026), biologics and injectables lines (Dec 2026) coming online |
| FY2026 | Zoladex transition completion; Ibtrogy uptake; Portrazza label-expansion data |
| FY2026 | Execution of the JPY 15 bn buyback (through Mar 2027); any further cross-shareholding sales |
| Feb 2027 | Q3 FY2026 results; FY2027 dividend signalling |
| Apr 2027 | NHI price revision impact on the oncology and biosimilar portfolio |
| May 2027 | FY2026 results and first Phase 1 progress review; potential M&A announcements |
| Ongoing | US tariff policy; Japan–China relations; JPY/USD and JPY/CNY rates; semiconductor cycle; gold prices |
Analyst verdict
Nippon Kayaku enters Evolution2035 with better operating momentum and clearer capital-allocation discipline than at any point in the past five years. The FY2023 collapse was triple-driven, by the semiconductor cycle, biosimilar price cuts and a front-loaded in-licensing charge, and it has fully reversed. Fine Chemicals now earns a record 16% margin on AI-server resin demand. Life Science profit rose 52% in FY2025 as Ibtrogy and new generics launched, and the group opened FY2026 with record first-quarter sales and an early upgrade. Management has matched this with tangible shareholder actions: about 13% of shares cancelled in roughly 18 months, systematic exit from cross-shareholdings and a total payout above 100%.
The investment case nevertheless hinges on margin repair rather than top-line growth. Sales have compounded at about 7% a year, yet operating margin is still two points below FY2021, and Mobility & Imaging remains a pass-through hostage to gold and explosive input costs. Free cash flow has been negligible through a heavy capex cycle. As a result, returns have been funded by monetising the balance sheet, a finite resource now that net cash is close to zero. The FY2028 targets of JPY 36 bn operating income and a 12% margin are ambitious against a history in which no year exceeded JPY 21.5 bn. Delivery depends on the delayed Asa epoxy plant, the ramp-up of the Takasaki and Toyama pharma capacity, and price discipline in safety products.
At about 13.8x forward earnings, 1.1x book and a 3.1% yield, the shares price in partial delivery. The rerating path is credible if 1H FY2026 confirms margin progress and FCF turns decisively positive as capex normalises. Overall assessment: constructive, with medium conviction. The quality of FY2026 operating-margin expansion and the FCF trajectory are the decisive monitorables, ahead of headline sales growth or further buybacks.
Source notes and data caveats
-
The company's results presentations and Evolution2035 Phase 1 deck (eir-parts.net) block automated retrieval. Phase 1 segment targets, the cash-allocation quantum, FY2025 business-unit actuals and the Q1 FY2026 segment detail are therefore not reproduced and should be verified against the original IR materials.
-
Q1 FY2026 consolidated operating income is reported by an aggregator as JPY 8.9 bn.
-
FY2023 geographic split: Yuho-derived data (overseas 38.2%) conflicts with management's stated 53.6%. A classification change is the likely cause.
-
Founder attribution differs between data vendors and a Japanese corporate-history source.
-
Board composition reflects the 19 June 2026 Yuho.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title / responsibility | Born (age) | Joined / board since | Prior roles | Shares held (k) |
|---|---|---|---|---|---|
Shigeyuki Kawamura | Representative Director, President & CEO; chairs the Board and the Nomination & Compensation Advisory Committee | 30 Jun 1963 (63) | Joined 1987; Director 2023; President Jun 2025 | Himeji Plant procurement head; GM, Kayaku (Huzhou) Safety Equipment (2016); Safety Systems planning head; Head of Safety Systems (2021); Director in charge of M&I and Safety Systems (2023) | 33 |
Hiroshi Shimada | Representative Director, Senior Managing Executive Officer; heads Life Science and Pharmaceuticals | 4 Jun 1965 (61) | Joined 1989; Director 2024; Representative Director Jun 2025 | President, Nippon Kayaku Food Techno (2018); Pharma API/International/Diagnostics head; Pharma planning | 30 |
Shinji Inoue | Director, Managing Executive Officer; Corporate Planning, Corporate Communications, Accounting, IT; Chair, Crisis Management Committee | 6 Feb 1966 (60) | Joined 1988; Director 2024 | GM, Shanghai Kayaku Trading (2011); Head of Colorants (2018); Head of Functional Materials (2023); Head of Fine Chemicals (2024) | 43 |
Makoto Takeda | Director, Managing Executive Officer; HR, Legal, General Affairs, Secretariat, Internal Control; Chair, Ethics Committee; export-control officer | 17 Jul 1964 (62) | Joined 1988; Director 2024 | Secretariat head; HR head | 19 |
Yasuhito Kato | Director, Managing Executive Officer; head of the Technology Division (R&D, RC/technology, sustainability metrics) | 3 Mar 1965 (61) | Joined 1990; Director 2025 | Head of Agro Research (2016); Head of Agro (2019) | 22 |
Yasuyuki Fujishima | Outside Director (independent) | 25 Mar 1947 (79) | Board 2016 | MITI; Ambassador to Panama; Executive Vice President, Sojitz; President, Gojokai Hosho | 16 |
Seiichi Fusamura | Outside Director (independent) | 18 Mar 1947 (79) | Board 2020 | Judge; Director-General, Civil Affairs Bureau, MOJ; Chief Judge of the Sendai and Nagoya High Courts; attorney | 0 |
Ikuko Akamatsu | Outside Director (independent) | 27 Feb 1968 (58) | Board 2023 | CPA and certified fraud examiner (ex-EY ShinNihon); board roles at SBI Shinsei Bank, Toyo Seikan, MUFG Securities and Brother Industries | 0 |
Mitsuhiro Tsubakimoto | Outside Director (independent) | 15 Oct 1959 (66) | Board 2025 | Toyota Tsusho senior executive (Asia-Pacific CEO; Chemicals & Electronics); President, Quaker Chemical Japan | 0 |
Directors' Remuneration
| Category | Total (JPY Mn) | Fixed | Performance-linked bonus | Restricted stock | Persons |
|---|---|---|---|---|---|
Inside directors | 366 | 197 | 126 | 42 | 7 |
Inside auditors | 47 | 47 | 0 | 0 | 3 |
Outside officers | 75 | 75 | 0 | 0 | 8 |
Shigeyuki Kawamura (President) | 111 | 55 | 41 | 14 | 1 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
28 Mar 2025 (effective 26 Jun 2025) | Atsuhiro Wakumoto (President since Jun 2019, aged 68) became Senior Advisor; Shigeyuki Kawamura (61, Safety Systems career) became President & CEO. Hiroshi Shimada became Representative Director. Yoshiji Ishida (Representative Director, Executive Vice President, planning, finance, IT, procurement) retired to become Special Advisor | Board said the new team should design and execute the next plan starting FY2026. Both new representative directors had pharma experience (Yakuji Nippo) |
Jun 2025 | Mitsuhiro Tsubakimoto joined as outside director; Yo Ota left the board (named in Yuho attendance records); Takeshi Saito replaced Megumi Machida as Standing Senior Auditor | Routine AGM rotation |
Nov 2025 | Inoue's portfolio narrowed: Procurement removed from his responsibilities | Organisational change |
Jun 2021 | Yukio Tachibana (Representative Director, Executive Vice President) retired; Tomoo Shibuya became Representative Director, Senior Managing Executive Officer | Jiho, May 2021 |
Major Shareholders
| Rank | Shareholder | Shares (k) | % |
|---|---|---|---|
| 1 | The Master Trust Bank of Japan (trust a/c) | 22,029 | 14.83 |
| 2 | Custody Bank of Japan (trust a/c) | 11,055 | 7.44 |
| 3 | Kaya Best Club (business-partner shareholding association) | 6,092 | 4.10 |
| 4 | The Joyo Bank | 5,089 | 3.43 |
| 5 | Meiji Yasuda Life Insurance | 4,843 | 3.26 |
| 6 | Northern Trust (AVFC) re Silchester International Investors International Value Equity Trust | 4,133 | 2.78 |
| 7 | Chugai Sangyo | 3,440 | 2.32 |
| 8 | MUFG Bank | 3,410 | 2.30 |
| 9 | Northern Trust (AVFC) re US Tax-Exempted Pension Funds | 2,791 | 1.88 |
| 10 | State Street Bank and Trust 505001 | 2,641 | 1.78 |
Competitive Landscape
Competitors by Segment
| Segment / product | Competitors | Relative positioning |
|---|---|---|
Airbag inflators | Daicel (Safety SBU; Japan), Autoliv (in-house inflators; Sweden/US), ZF (Germany), Joyson Safety Systems (China/US), ARC Automotive (US) | NK is a merchant (non-module) inflator supplier with strong Chinese local-OEM exposure. Autoliv is the global safety-module leader (2025 sales ≈ USD 10.8 bn) |
MGGs and squibs | Daicel, Autoliv, ZF, Joyson | NK claims the No. 1 global share in MGGs (company) |
Polarisers / optical (niche) | Nitto Denko, Sumitomo Chemical (mass LCD polarisers); niche HUD optics makers | NK competes only in high-durability dye-based and niche optical segments |
X-ray components | Hamamatsu Photonics, Amptek (Ametek), Ketek | Moxtek and Rayspec are niche specialists |
Semiconductor epoxy resins | DIC (expanding Chiba epoxy plant by about 59%), Mitsubishi Chemical, Nippon Steel Chemical & Material, Resonac | NK cited as world No. 1 in encapsulant epoxy (Monex profile); a DIC capacity build is a share threat |
MEMS / thick-film resists | DuPont, JSR, Tokyo Ohka Kogyo, Merck | SU-8 franchise via KAM |
Inkjet and functional dyes | Fujifilm, Orient Chemical, Sumitomo Chemical, Huntsman (textile dyes) | NK described as Japan's largest dye maker (Monex profile) |
Acrylic-acid catalysts | Mitsubishi Chemical and Nippon Shokubai (captive), BASF, Clariant | NK claims the No. 1 global merchant share (company) |
Oncology generics and biosimilars (Japan) | Sawai Group, Towa Pharmaceutical, Nichi-Iko, Daiichi Sankyo Espha, Pfizer, Celltrion, Fuji Pharma | NK is a leading domestic oncology supplier (company) |
Innovative oncology (Japan) | Chugai, Daiichi Sankyo, Takeda, AstraZeneca, Pfizer (ROS1: crizotinib; Chugai's entrectinib; BMS's repotrectinib) | Ibtrogy is the fourth ROS1 TKI in Japan |
Agrochemicals | Kumiai Chemical, Nihon Nohyaku, Sumitomo Chemical, Nissan Chemical | Niche player |
Peer Comparison FY2025
| Metric | Nippon Kayaku (FY to Mar-2026) | Daicel (FY to Mar-2026) | DIC (FY to Dec-2025) | Autoliv (FY to Dec-2025) |
|---|---|---|---|---|
Revenue | JPY 241.9 bn | JPY 579.6 bn | JPY 1,052.2 bn | ≈ USD 10.8 bn |
Revenue growth YoY | +8.7% | -1.2% | -1.8% | +4.1% |
Operating margin | 9.3% | 7.3% | 5.0% | ≈ 10.0% |
Net income attributable | JPY 24.6 bn | JPY 10.2 bn (JPY 32.8 bn COC-resin impairment) | JPY 32.4 bn |
|
R&D / sales | 5.2% (total R&D basis) | — | — | — |
Current-year guidance | Sales JPY 270.9 bn; OI JPY 27.3 bn | Sales JPY 595 bn; OI JPY 42.5 bn | Sales JPY 1.1 tn; OI JPY 56 bn | Organic growth ≈0%; adj. margin 10.5–11.0% |
Recent Developments
Special retirement payments of JPY 335 M (FY2024) and JPY 100 M (FY2025) were booked. Consolidated headcount fell slightly (−33) in FY2025.
In 2024, Japan's OEM type-certification irregularities depressed first-half FY2024 domestic Safety Systems volumes (company commentary, Nov 2024 briefing).



